Hoffman ALS Clinical Trial Awards Program

The Hoffman ALS Clinical Trial Awards Program sits under The ALS Association and funds early- to mid-stage phase 1 or phase 2a clinical trials for ALS. It supports novel or repurposed therapeutics, either disease-modifying or symptomatic, and imaging tracers, with total awards of up to $1,000,000 over two or three years. The program is open to academic and industry investigators worldwide. It expects strong biological rationale, robust preclinical data, an integrated biomarker strategy, and explicit go/no-go milestones, and it requires IND-enabling work to be complete or nearly complete by the full-proposal date. IND or equivalent approval is required at award time. The 2026 cycle runs in two stages, with an LOI followed by invitation-only full proposal through ProposalCentral. Co-funding is typically expected, and the program is especially interested in TDP-43 and protein aggregation. That makes it a fit for teams that already have a disciplined trial design and a credible route to de-risk an ALS program.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.